Alpert M A, Curtis J J, Sanfelippo J F, Flaker G C, Walls J T, Mukerji V, Villarreal D, Katti S K, Madigan N P, Morgan R J
Am Heart J. 1987 Apr;113(4):958-65. doi: 10.1016/0002-8703(87)90057-3.
To determine whether survival following permanent ventricular demand pacing differs from survival following permanent dual-chamber pacing in patients with symptomatic sinus node dysfunction (unexplained sinus bradycardia, subsidiary rhythms, sinus arrest, sinoatrial block, or the bradycardia/tachycardia syndrome), we followed 79 patients who received a VVI pacemaker (group 1) and 49 patients who received a DVI or DDD pacemaker (group 2) for 1 to 5 years. There was no significant difference in sex distribution, mean age, or the incidence of coronary heart disease, hypertension, valvular heart disease, diabetes mellitus, stroke, or renal failure between groups 1 and 2. Overall, the predicted cumulative survival rates at 1, 3, and 5 years were 89%, 82%, and 74%, respectively, for group 1 and 94%, 86%, and 78%, respectively, for group 2. In patients with preexistent congestive heart failure (CHF), predicted cumulative survival rates at 1, 3, and 5 years were 78%, 69%, and 57%, respectively, for group 1 (n = 23) and 90%, 83%, and 75%, respectively, for group 2 (n = 16). Five-year predicted cumulative survival was significantly lower in group 1 patients with CHF than in group 2 patients with CHF (p less than 0.03). There was no significant difference in 5-year cumulative survival rates between groups 1 and 2 in patients without CHF. The results suggest that permanent dual-chamber pacing enhances survival to a greater extent than permanent ventricular demand pacing in patients with chronic symptomatic sinus node dysfunction and CHF.
为了确定有症状的窦房结功能障碍(不明原因的窦性心动过缓、逸搏心律、窦性停搏、窦房阻滞或心动过缓/心动过速综合征)患者接受永久性心室按需起搏后的生存率是否不同于接受永久性双腔起搏后的生存率,我们对79例接受VVI起搏器的患者(第1组)和49例接受DVI或DDD起搏器的患者(第2组)进行了1至5年的随访。第1组和第2组在性别分布、平均年龄或冠心病、高血压、瓣膜性心脏病、糖尿病、中风或肾衰竭的发生率方面没有显著差异。总体而言,第1组1年、3年和5年的预测累积生存率分别为89%、82%和74%,第2组分别为94%、86%和78%。在已有充血性心力衰竭(CHF)的患者中,第1组(n = 23)1年、3年和5年的预测累积生存率分别为78%、69%和57%,第2组(n = 16)分别为90%、83%和75%。第1组有CHF的患者5年预测累积生存率显著低于第2组有CHF的患者(p小于0.03)。在没有CHF的患者中,第1组和第2组的5年累积生存率没有显著差异。结果表明,在慢性有症状的窦房结功能障碍和CHF患者中,永久性双腔起搏比永久性心室按需起搏在更大程度上提高生存率。